169 related articles for article (PubMed ID: 12829603)
1. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Wesley R; Wang QJ; Barrett AJ
Blood; 2003 Oct; 102(8):3025-7. PubMed ID: 12829603
[TBL] [Abstract][Full Text] [Related]
2. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Nam JM; Robyn J; Loberiza F; Maciejewski JP; Simonis T; Molldrem J; Young NS; Barrett AJ
Blood; 2002 Sep; 100(5):1570-4. PubMed ID: 12176872
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.
Barrett AJ; Sloand EM
Curr Hematol Malig Rep; 2008 Jan; 3(1):23-8. PubMed ID: 20425443
[TBL] [Abstract][Full Text] [Related]
6. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
[TBL] [Abstract][Full Text] [Related]
7. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
8. [Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution].
Miyata A; Yasuda Y; Fujii S; Kikuchi T
Rinsho Ketsueki; 2002 Oct; 43(10):911-7. PubMed ID: 12462026
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C; Braun T; Arana R; Marceau-Renaut A; Lazarian G; Soret J; Cereja S; Letestu R; Eclache V; Lusina D; Baran-Marszak F; Ades L; Preudhomme C; Martin A; Fenaux P; Gardin C
Leuk Res; 2018 Aug; 71():67-74. PubMed ID: 30025278
[TBL] [Abstract][Full Text] [Related]
10. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome.
Biesma DH; van den Tweel JG; Verdonck LF
Cancer; 1997 Apr; 79(8):1548-51. PubMed ID: 9118037
[TBL] [Abstract][Full Text] [Related]
12. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
Kadia TM; Borthakur G; Garcia-Manero G; Faderl S; Jabbour E; Estrov Z; York S; Huang X; Pierce S; Brandt M; Koller C; Kantarjian HM; Ravandi F
Br J Haematol; 2012 May; 157(3):312-20. PubMed ID: 22360602
[TBL] [Abstract][Full Text] [Related]
13. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment.
Barrett J; Sloand E; Young N
Haematologica; 2006 May; 91(5):583-4. PubMed ID: 16670061
[No Abstract] [Full Text] [Related]
14. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.
Parikh AR; Olnes MJ; Barrett AJ
Semin Hematol; 2012 Oct; 49(4):304-11. PubMed ID: 23079060
[TBL] [Abstract][Full Text] [Related]
15. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia.
Yoshimi A; Baumann I; Führer M; Bergsträsser E; Göbel U; Sykora KW; Klingebiel T; Gross-Wieltsch U; van den Heuvel-Eibrink MM; Fischer A; Nöllke P; Niemeyer C
Haematologica; 2007 Mar; 92(3):397-400. PubMed ID: 17339190
[TBL] [Abstract][Full Text] [Related]
17. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy for patients with refractory anemia.
Asano Y; Maeda M; Uchida N; Yokoyama T; Osaki K; Shimoda K; Gondo H; Okamura T; Okamura S; Niho Y
Ann Hematol; 2001 Nov; 80(11):634-8. PubMed ID: 11757721
[TBL] [Abstract][Full Text] [Related]
19. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.
Steensma DP; Dispenzieri A; Moore SB; Schroeder G; Tefferi A
Blood; 2003 Mar; 101(6):2156-8. PubMed ID: 12411290
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
